---
title: "Lunai Bioworks Announces 1-for-8 Reverse Stock Split"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/287078709.md"
description: "Lunai Bioworks, Inc. announced a 1-for-8 reverse stock split effective May 22, 2026, to comply with Nasdaq's minimum bid requirement. This move reduces outstanding shares from 36.3 million to 4.5 million, following a previous 1-for-10 split in September 2025. The consolidation aims to enhance share price and trading liquidity while maintaining the par value and authorized share count. The company focuses on AI-driven drug development in CNS and oncology markets."
datetime: "2026-05-20T13:51:21.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/287078709.md)
  - [en](https://longbridge.com/en/news/287078709.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/287078709.md)
---

# Lunai Bioworks Announces 1-for-8 Reverse Stock Split

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

The latest announcement is out from Lunai Bioworks ( (LNAI) ).

Lunai Bioworks, Inc. announced on May 20, 2026, that it will implement a 1-for-8 reverse stock split of its common shares, effective at 12:01 a.m. Eastern Time on May 22, 2026, with trading on the Nasdaq Capital Market to begin on a split-adjusted basis the same day under ticker LNAI and a new CUSIP. The move, approved by shareholders at a May 8, 2026 special meeting and following a prior 1-for-10 reverse split in September 2025, will shrink outstanding shares from about 36.3 million to 4.5 million and is primarily aimed at lifting the share price to restore compliance with Nasdaq’s minimum bid requirement, with proportional adjustments applied to outstanding equity-linked securities and no fractional shares issued.

The reverse stock split will consolidate every eight existing shares into one while leaving the par value and authorized share count unchanged, potentially affecting trading liquidity and volatility for investors. Stockholders’ positions will be automatically adjusted through the company’s transfer agent and intermediaries, and the action underscores Lunai Bioworks’ efforts to preserve its Nasdaq listing as it continues developing AI-enabled precision drugs in CNS and oncology markets.

**More about Lunai Bioworks**

Lunai Bioworks, Inc. is an AI-driven life sciences company that applies an integrated platform combining clinical data, machine learning and in vivo validation to advance drug discovery and chemical defense. The company focuses on central nervous system diseases and oncology, aiming to develop precision therapeutics that shorten development timelines and improve clinical success rates.

**Average Trading Volume:** 21,785,490

**Technical Sentiment Signal:** Strong Sell

**Current Market Cap:** $9.38M

See more data about LNAI stock on TipRanks’ Stock Analysis page.

### Related Stocks

- [LNAI.US](https://longbridge.com/en/quote/LNAI.US.md)
- [RENB.US](https://longbridge.com/en/quote/RENB.US.md)

## Related News & Research

- [Trillion-dollar Samsung faces a battle over who gets the AI profits](https://longbridge.com/en/news/287013238.md)
- [Citadel CEO Ken Griffin was a prominent AI skeptic. Now he says, 'AI is real.'](https://longbridge.com/en/news/286683665.md)
- [Singapore Leads Emerging Race to Become World’s First «Trusted AI Financial Hub»](https://longbridge.com/en/news/287063092.md)
- [eClerx Unifies AI Leadership to Deliver Outcome-Driven Results at Enterprise Scale](https://longbridge.com/en/news/287096511.md)
- [Oracle stock: 'Light at the end of the tunnel' seen for big AI spending](https://longbridge.com/en/news/287098163.md)